NanoViricides' NV-387 Antiviral Drug Shows Promise in Reducing Metastatic Cancer Resurgence Due to Viral Infections

NanoViricides' broad-spectrum antiviral drug NV-387 has completed a Phase I clinical trial and is advancing to Phase II trials. The drug reduces inflammation, which has been linked to an increased risk of metastatic cancer resurgence due to viral infections. NV-387 treatment could help protect cancer patients in remission from viral infections that could lead to cancer returning with metastasis.

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC), has announced that its broad-spectrum antiviral drug NV-387 has successfully completed Phase I clinical trials and is now advancing to Phase II trials. The drug, developed using host-mimetic nanomedicine technology, has shown promise in reducing inflammation, which has been linked to an increased risk of metastatic cancer resurgence due to viral infections [1].

NV-387 is unique in that it not only attacks the virus but also reduces inflammation, calming the human immune system and minimizing untoward effects. The drug has been found to reduce inflammation markers, particularly IL-6, thereby protecting lungs and potentially minimizing the risk of reawakening cancer cells [2].

The need for such a drug is underscored by the ongoing COVID-19 pandemic and other endemic viruses like Influenza and RSV, which can cause severe lung diseases. NV-387 has demonstrated effectiveness against these viruses in animal model studies, outperforming existing treatments like Tamiflu and Rapivab [3].

The company's lead drug candidate, NV-387, is being developed to treat RSV, COVID-19, Long COVID, Influenza, and other respiratory viral infections. It is also exploring applications for MPOX/Smallpox infections. NanoViricides' platform technology is based on the TheraCour® nanomedicine technology, which is licensed from AllExcel [4].

The advancement to Phase II trials marks a significant milestone for NanoViricides, as it brings the drug one step closer to potential clinical approval and market availability. However, it is important to note that the path to drug development is lengthy and fraught with risks, including regulatory approvals and market acceptance [5].

References:
[1] https://news.cuanschutz.edu/cancer-center/covid-19-awaken-dormant-cancer-cells
[2] Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2025, August 18. https://covid.cdc.gov/covid-data-tracker
[3] https://www.morningstar.com/news/accesswire/1061948msn/a-drug-that-could-reduce-metastatic-cancer-resurgence-due-to-its-anti-inflammatory-effects-in-viral-infections-is-in-clinical-trials
[4] https://www.nanoviricides.com
[5] NanoViricides, Inc.